Biopharma and resources-pooling company Atai Life Sciences (NASDAQ: ATAI) has invested a total of $50 million in Beckley Psytech Ltd., a U.K.-based clinical-stage biotech advancing short-duration psychedelics for neuropsychiatric conditions.
Biopharma company Atai Life Sciences (NASDAQ: ATAI) shared positive results from a Phase 1 clinical study on MDMA R-enantiomer, EMP-01, under development for the potential treatment of PTSD.
The psychedelic drug market is projected to soar to $7.2 billion by 2029, reflecting a 55% compound annual growth rate (CAGR) and further showing its power.
A new meta-analysis identifies specific brain regions involved in treatment response in bipolar and borderline personality disorders, potentially paving the way for more targeted treatment.
Succession season four sees Alexander Skarsgard return as Lukas Matsson - but if the Roys are loosely based on the Murdoch family, is there a real-life counterpart for Lukas?
Most antipsychotics have weight-related and metabolic side effects. This study shines a light on the relationship of dose and weight for each agent to help inform which antipsychotic to prescribe.
Mood stabilizers, particularly lithium, are tied to lower mortality rates, including suicide and naturally occurring death, in patients with bipolar disorder.
Long-term antidepressant use is tied to an increased risk of adverse outcomes, including cardiovascular disease and all-cause mortality, a new study suggests. However, the mechanism remains unclear.